Crescent Energy Company Class A Common Stock vs Quest Diagnostics Inc — how do they compare? Crescent Energy Company Class A Common Stock trades at $12.71 (market cap $4.30B), while Quest Diagnostics Inc trades at $229.97 (market cap $25.48B). The key difference: Quest Diagnostics Inc is far larger — about 5.9× Crescent Energy Company Class A Common Stock's market cap, and Crescent Energy Company Class A Common Stock pays the higher dividend (3.69%). Which is the better fit depends on your goals — on Pluang, investors hold Crescent Energy Company Class A Common Stock for 1 Days and Quest Diagnostics Inc for 56 Days on average.
| CRGY | DGX | |
|---|---|---|
Market Cap | $4.30B | $25.48B |
Volume | 15,201,625 | 941,866 |
Sector | Energy | Health |
52-Week High | $15.37 | $247.45 |
52-Week Low | $7.75 | $173.49 |
Typical Hold Time | 1 Days | 56 Days |
Enterprise Value | $9.31B | $31.23B |
Dividend Yield | 3.69% | 1.49% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Trailing returns across standard periods
Crescent Energy acquires, develops, and produces oil and natural gas from onshore U.S. basins. Its portfolio includes producing assets with oil and natural gas exposure.
Read more on CRGY →Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →